OCGN

$0.75+2.83%visit website

Ocugen, Inc.

Market Cap

$253M

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.98

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

55.2

TTM to Jun 2026 · revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	1,752	(193)	1,533	1,488	4,580
Research & development	11,149	10,669	11,255	10,690	43,763
Total operating expenses	19,377	16,802	19,372	17,932	73,483
Operating income	(17,625)	(16,995)	(17,839)	(16,444)	(68,903)
Interest expense	1,314	1,332	1,320	4,476	8,442
Net income	(20,051)	(17,706)	(19,177)	(24,877)	(81,811)
EPS (basic) ($)			(0.06)	(0.07)
EPS (diluted) ($)			(0.06)	(0.07)
Weighted avg. shares (basic)			327,544	338,680
Weighted avg. shares (diluted)			327,544	338,680

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 46 more quarters, back to Mar 2014, with Tormere Pro.

Corporate Events (8-K)

25 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Oct 15, 2026 accepted 12:01 PM ET	7.01Reg FD disclosure	Document SEC ↗
Oct 15, 2026 accepted 1:22 AM ET	1.01Material agreement7.01Reg FD disclosure8.01Other events	Document SEC ↗
Oct 6, 2026 accepted 9:36 PM ET	5.07Shareholder vote	Document SEC ↗
Sep 23, 2026 accepted 9:34 PM ET	5.07Shareholder vote	Document SEC ↗
Sep 8, 2026 accepted 9:27 PM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
Aug 6, 2026 accepted 12:30 PM ET	2.02Earnings release	Document SEC ↗
Jul 13, 2026 accepted 12:30 PM ET	8.01Other events	Document SEC ↗
Jun 11, 2026 accepted 9:19 PM ET	5.07Shareholder vote8.01Other events	Document SEC ↗
Jun 3, 2026 accepted 8:30 PM ET	5.02Officer / director change	Document SEC ↗
May 14, 2026 accepted 8:31 PM ET	5.02Officer / director change8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

66%

W/W +14.8pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

23.98x

Avg Daily Selling (90d)

11,689 sh/day

Baseline Daily Selling

0.0 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-09	2026-10-13	Musunuri Shankar	Director & Chief Executive Officer	Sale	526.0K	$0.95	$500K	1.03M	View
2026-09-09	2026-09-11	Musunuri Shankar	Director & Chief Executive Officer	Sale	526.0K	$1.12	$589K	1.09M	View
2026-06-15	2026-06-17	Johnson-Greene Treerita Essalima	Chief Financial Officer	Purchase	21.0K	$1.23	$26K	521.0K	View

Recent News

My 'Eye' Is On Tarsus Pharmaceuticals

SeekingAlpha · 2026-11-01

Ocugen to Participate in Upcoming November Investor and Industry Conferences

Yahoo · 2026-10-29

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

Yahoo · 2026-10-22

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Yahoo · 2026-10-14

Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region

Benzinga · 2026-10-14

Ocugen CEO Shankar Musunuri sells $499,691 of company stock

Investing.com · 2026-10-13

An officer proposes selling 525,991 Ocugen (OCGN) shares through Merrill Lynch.

Stock Titan · 2026-10-09

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Yahoo · 2026-10-06

Transcript: Ocugen Q2 2026 Earnings Conference Call

Benzinga · 2026-10-06

Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight

Yahoo Finance · 2026-09-29

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Yahoo Finance · 2026-09-25

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Yahoo Finance · 2026-09-25

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances

Yahoo Finance · 2026-09-16

$OCGN stock is down 14% today. Here's what we see in our data.

Quiver Quantitative · 2026-09-09

OCGN Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

Informational purposes only, not investment advice.

OCGN

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

Ocugen, Inc. (OCGN)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-10-09	Musunuri Shankar	S	468,727	$445,290.65
2026-10-09	Musunuri Shankar	S	57,264	$54,400.8
2026-09-09	Musunuri Shankar	S	468,727	$524,974.24
2026-09-09	Musunuri Shankar	S	57,264	$64,135.68
2026-06-15	Johnson-Greene Treerita Essalima	P	21,000	$25,830